Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2024 18:40 ET
|
Rapid Micro Biosystems, Inc.
LOWELL, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation...
Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Guidance
March 01, 2024 06:30 ET
|
Rapid Micro Biosystems, Inc.
Reports fourth quarter 2023 total revenue of $6.3 million, representing 45% growth compared to fourth quarter 2022 Reports 2023 revenue of $22.5 million, representing 31% growth compared to 2022 ...
Rapid Micro Biosystems to Participate in Upcoming Investor Conferences
February 27, 2024 16:30 ET
|
Rapid Micro Biosystems, Inc.
LOWELL, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation...
Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024
February 20, 2024 16:36 ET
|
Rapid Micro Biosystems, Inc.
LOWELL, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation...
Rapid Micro Biosystems Announces the Upcoming Availability of Rapid Sterility Application for the Growth Direct® System
January 10, 2024 07:22 ET
|
Rapid Micro Biosystems, Inc.
The new Rapid Sterility application includes a novel, proprietary test kit that has been developed for use with the Company’s fully automated Growth Direct system and delivers time to organism...
Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenue
January 10, 2024 07:20 ET
|
Rapid Micro Biosystems, Inc.
Full year 2023 total revenue expected to be between $22.4 million and $22.6 million, representing growth of over 30% compared to the prior year Fourth quarter 2023 total revenue expected to be...
Samsung Biologics เลือกแพลตฟอร์ม Growth Direct® ของ Rapid Micro Biosystems เพื่อทำการทดสอบการควบคุมคุณภาพทางจุลชีววิทยาที่สำคัญโดยอัตโนมัติ
January 04, 2024 09:18 ET
|
Rapid Micro Biosystems, Inc.
โลเวลล์ แมสซาชูเซตส์ , Jan. 04, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (“บริษัท”)...
Samsung Biologics, 주요 미생물 품질 관리 테스트 공정 자동화를 위해 Rapid Micro Biosystems의 Growth Direct® 플랫폼 채택
January 04, 2024 09:18 ET
|
Rapid Micro Biosystems, Inc.
매사추세츠주 로웰, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- 회사가 핵심과제로 삼은 자동화 솔루션을 통해 헬스케어 제품의 효율적인 제조와 신속하고 안전한 출시를 지원하는 혁신적인 생명과학 기술 기업인 Rapid Micro Biosystems, Inc. (래피드 마이크로 바이오시스템즈) (나스닥: RPID) (이하...
サムスンバイオロジクス （Samsung Biologics）、重要な微生物の品質管理テスト自動化にラピッド・マイクロ・バイオシステムズ (Rapid Micro Biosystems) のグロースダイレクト (Growth Direct®) プラットフォームを選択
January 04, 2024 09:18 ET
|
Rapid Micro Biosystems, Inc.
マサチューセッツ州ローウェル発, Jan. 04, 2024 (GLOBE NEWSWIRE) -- ヘルスケア製品の効率的な製造と迅速かつ安全なリリースを促進するミッションクリティカルな自動化ソリューションを提供する革新的なライフサイエンステクノロジー企業であるラピッド・マイクロ・バイオシステムズ (Rapid Micro Biosystems, Inc.) (NASDAQ: RPID)...
Samsung Biologics 選擇 Rapid Micro Biosystems 的 Growth Direct® 平台以自動化關鍵微生物品質控制測試
January 04, 2024 09:18 ET
|
Rapid Micro Biosystems, Inc.
羅威爾，麻薩諸塞州, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID)（以下簡稱「公司」）是一間創新生命科學技術公司，提供關鍵任務自動化解決方案，以促進醫療保健產品的高效生產和快速、安全發布。該公司今日宣布 Samsung Biologics (KRX: 207940.KS) 選擇了...